TARRYTOWN, N.Y., May 23 /PRNewswire-FirstCall/ -- Emisphere
Technologies, Inc. (Nasdaq: EMIS) will host its Annual Shareholders Meeting
on Thursday, May 25, 2006 at the Westchester Marriott Hotel, 670 White
Plains Road, Tarrytown, NY, beginning at 10:00 a.m., Eastern Daylight Time.
Webcast Information
For those shareholders who are unable to attend, Emisphere will webcast
the meeting. To access the live broadcast via Internet in listen-only mode,
or the subsequently archived recording, please go to the Upcoming Events
page in the Investor Relations portion of the Company's web site at:
http://phx.corporate-ir.net/phoenix.zhtml?p=irol-
eventDetails&c=78250&eventID=1310919
Please visit the site at least five minutes prior to start time for
instructions.
About Emisphere Technologies, Inc.
Emisphere Technologies, Inc. is a biopharmaceutical company pioneering
the oral delivery of otherwise injectable drugs. Emisphere's business
strategy is to develop oral forms of drugs that are not currently available
or have poor bioavailability in oral form, either alone or with corporate
partners, by applying its proprietary eligen(R) technology to those drugs
or licensing its eligen(R) technology to partners who typically apply it
directly to their marketed drugs. Emisphere's eligen(R) technology has
enabled the oral delivery of proteins, peptides, macromolecules and charged
organics. Emisphere and its partners have advanced oral formulations or
prototypes of heparin, insulin, salmon calcitonin, parathyroid hormone,
human growth hormone and cromolyn sodium into clinical trials. Emisphere
has strategic alliances with world- leading pharmaceutical companies. For
further information, please visit our web site, http://www.emisphere.com.
Safe Harbor Statement Regarding Forward-looking Statements
The statements in this release and oral statements made by
representatives of Emisphere relating to matters that are not historical
facts (including without limitation those regarding the timing or potential
outcomes of research collaborations or clinical trials, any market that
might develop for any of Emisphere's product candidates and the sufficiency
of Emisphere's cash and other capital resources) are forward-looking
statements that involve risks and uncertainties, including, but not limited
to, the likelihood that future research will prove successful, the
likelihood that any product in the research pipeline will receive
regulatory approval in the United States or abroad, the ability of
Emisphere and/or its partners to develop, manufacture and commercialize
products using Emisphere's drug delivery technology, Emisphere's ability to
fund such efforts with or without partners, and other risks and
uncertainties detailed in Emisphere's filings with the Securities and
Exchange Commission (the "SEC"), including those factors discussed under
the caption "Risk Factors" in Emisphere's Annual Report on Form 10-K (file
no. 1-10615) filed on March 16, 2006.
SOURCE Emisphere Technologies, Inc.
 back to top
Related links:
http://www.emisphere.com/
CONTACT:
Investor Relations: Emisphere Technologies,
Inc., +1-914-785-4742; or Media: Dan Budwick of BMC
Communications, +1-212-477-9007, ext. 14, for Emisphere
Technologies, Inc.
|
